Compare Abeona Therapeutics Inc (ABEO) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs First Trust Cloud Computing ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while First Trust Cloud Computing ETF trades at $138.07. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, First Trust Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | SKYY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $155.17 |
52-Week Low | $4.17 | $104.16 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SKYY, the First Trust Cloud Computing ETF, trades at $139.01, up 3.08% today, with a bullish technical signal from moving averages but mixed oscillators. The ETF provides diversified exposure to the cloud computing sector, which is benefiting from enterprise digital transformation and AI adoption. Recent news highlights strong inflows into technology ETFs and the launch of AI tools to aid investment decisions.
The outlook for SKYY is positive, driven by sustained demand for cloud services and AI integration, though risks include sector volatility and competitive pressures. Investors should monitor earnings growth of underlying holdings and broader tech sector trends for continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
